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With continued advancements in medical practice, physicians are caring for more adult patients with
congenital heart diseases and their sequelae. We report a 51 year-old with obstructive sleep apnea
presenting with dyspnea, hypoxia and pulmonary hypertension, found to have a congenital atrial septal
defect. The patient had symptomatic improvement following percutaneous closure of his ostium
secundum atrial septal defect.
 2009 Elsevier Ltd. All rights reserved.A 51-year-old man presented with 10 days of progressive
dyspnea. His symptoms began as an upper respiratory infection,
but had progressed to include chills and a cough productive of
yellow sputum. He had also developed dyspnea at rest. Initially,
moxiﬂoxacin and bronchodilators produced some symptomatic
improvement. His past medical history was signiﬁcant for pulmo-
nary hypertension, conﬁrmed by right heart catheterization four
months prior, with a mean PA pressure of 42 mmHg four months
prior to admission. A recent polysomnogram had demonstrated
obstructive sleep apnea (AHI 53, O2 sat less than 88% for 386 min or
97% of the study), but he had not been started on therapy. He took
no daily outpatient medications. Occasionally he used acetamino-
phen, sennakot, diphenhydramine, omeprazole, and zolpidem. He
had a 20 pack-year smoking history, but quit 18 years prior. He was
retired and had worked as a painter, plumber and construction
laborer. He had served in the Navy, and recalled no exposure to
asbestos. He had one cat and could recall no sick contacts.
His physical exam revealed an obese white male who appeared
fatigued, but in no acute distress. He was able to speak in full
sentences. Vital signs revealed a blood pressure of 114/76, heart rate
96 bpm, respiratory rate 22, and an oxygen saturation of 88% while
breathing room air. This improved to 90% on 2 L/min by nasal
cannula. Further increases in supplemental oxygen did not signif-
icantly increase his oxygen saturations. Mucous membranes were
moist with no oral lesions. ENT exam demonstrated a Mallampati
score was 3, no cervical adenopathy, thyromegaly or upper airway
wheeze. Cardiovascular exam revealed a normal rhythm without
murmurs or gallops and a prominent split and ﬁxed S2. Neck veins
were not distended. Lungs had rhonchi at the bases with good air
movement bilaterally. Abdomen was soft and non-tender with: þ1 317 988 3976.
rved.normal bowel sounds and no palpable organomegaly. Extremities
revealed no clubbing, cyanosis or edema. Pulses were 2þ periph-
erally. Skin revealed tinea versicolor over the arms and chest, but
was otherwise normal.
Labs demonstrated normal blood cell counts and differential.
Chemistry was notable only for a mildly elevated creatinine at
1.2 mg/dL. BNP was 12 pg/mL, and d-dimer, cardiac markers and
TSH were normal. HIV ELISA, RF, ANA and ESR were all low or
negative. Room air arterial blood gas demonstrated a pH of 7.46,
pCO2 of 35, and a pO2 of 58. CXR suggested a possible retrocardiac
inﬁltrate and left atrial dilation (see Fig. 1). A CT scan of the chest
with IV contrast showed no central pulmonary emboli, normal lung
parenchyma and enlarged pulmonary arteries. Pulmonary function
tests revealed an FVC 4.55 L (88%), FEV1 3.24 L (81%) and diffusing
capacity adjusted for hemoglobin at 22.1 (72%). One year prior to
admission, an echocardiogram showed a left ventricular ejection
fraction (LVEF) of 51% with normal LV systolic function, mild dila-
tation of all four chambers of the heart with mild concentric left
ventricular hypertrophy. Right ventricular systolic pressure was
estimated at 50 mmHg. A right heart catheterization performed
four months prior to admission measured pulmonary arterial
pressure (PAP) at 69/30 mmHg (42), right ventricular pressure
(RVP) 68/14 mmHg, pulmonary capillary wedge pressure (PCWP)
20 and pulmonary vascular resistance (PVR)was 308 dyne-sec/cm.5
Repeat contrast echocardiogram showed normal left ventricular
systolic functionwith LVEF estimated at 49% with mild to moderate
chambers dilatation. A ﬂattened septumwas noted during diastole,
consistent with RV volume overload. The right ventricular systolic
pressure was estimated at 65–70 mmHg and a left-to-right shunt
was demonstrated at the atrial level (Fig. 2). Repeat right heart
catheterization revealed: PAP 60/26 (38) mmHg, RVP 56/6 mmHg,
PCWP 10 mmHg, PVR 5.4 Woods units, CO/CI 5.18/2.37 (using the
Fick method). Oxygen saturations were 64% at the superior vena
cava, 70% at the inferior vena cava, RA 74% in the right atrium, 71%
Table 1
Differential diagnosis of pulmonary hypertension.
WHO Class 1 (PAH)
 Idiopathic
 Familial
 Collagen vascular disease
 Congenital systemic to pulmonary shunts
 Portal hypertension
 HIV
 Drugs or toxins
 Veno-occlusive disease
 Capillary hemangiomatosis
 Persistent pulmonary hypertension of the newborn
 Other: Thyroid disease,
Glycogen storage disease, Gaucher disease
Hereditary hemorrhagic telangiectasias
Hemoglobinopathies, Splenectomy
Myeloproliferative disease
WHO Class 2 (Pulmonary Venous Hypertension)
 Left-sided atrial or ventricular disease
 Left-sided valvular disease
 Extrinsic compression of pulmonary veins
WHO Class 3 (Disorders of the Respiratory System or Hypoxemia)
 COPD
 Interstitial lung disease
 Sleep disordered breathing/OSA
 Hypoventilation disorders
 Chronic exposure to high-altitude
Fig. 1. CXR showing sign of left atrial dilation.
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(pulmonary to systemic ﬂow ratio) was 1.23, although this was felt
to be decreased from the actual value due to a bidirectional shunt at
the atrial level. Developmental abnormalities
WHO Class 4 (Thromboembolic Diseases)
WHO Class 5 (Miscellaneous)
 Sarcoidosis
 Langerhans cell histiocytosis
 Extrinsic compression of pulmonary vessels
 Lymphangiomatosis
Recreated based on Table1 in: Diagnosis and Treatment of Secondary (Non Category
1) Pulmonary Hypertension. Rich, Stewart and Marlene Rabinovitch. Circulation
2008: 118: 2190-2199.2. Diagnosis
Congenital atrial septal defect (ASD) and obstructive sleep apnea
diagnosed in an adult manifest as pulmonary hypertension,
hypoxia, and right-to-left shunt.
Pulmonary hypertension is common and its incidence probably
underappreciated. It is often found concomitantly with other
cardiopulmonary diseases and the differential for its etiology is
wide (Table 1).11 Pulmonary hypertension is found in 17–52% of
patients with OSA.6 Nocturnal hypoxia acutely causes pulmonary
vasoconstriction, and it is believed that recurrent hypoxic episodes
in patients with obstructive sleep apnea cause vascular remodeling
and subsequent pulmonary hypertension. Our patient hadFig. 2. Trans-esophageal echocardiographic images showing agitated saline bubbles
crossing from the right to the left atrium through the ASD (arrowhead).obstructive sleep apnea, which was initially felt to be a cause of his
pulmonary hypertension. Patients with obstructive sleep apnea
also often have an elevated wedge pressure during exercise. This
implies that exercise-induced pulmonary hypertension seen in this
subset of patients may be due to a post-capillary cause of pulmo-
nary hypertension related to left ventricular diastolic dysfunction.
Supplemental oxygen, tracheotomy and CPAP have been shown to
lower pulmonary artery pressures in patients with obstructive
sleep apnea.6 Pulmonary hypertension attributed to obstructive
sleep apnea is almost always mild when not associated with an
underlying lung disease.9,12,13
Given the degree of pulmonary hypertension in this patient, it is
most likely that his pulmonary hypertension was caused primarily
by his atrial septal defect. Adults with congenital heart disease now
outnumber children, present in more than one million adults in the
United States with many shunt lesions are diagnosed later in life.
The incidence of ASD is 4 in 100,000 live births. The most common
type of ASD is the ostium secundum defect. Symptoms of an ASD
include exercise intolerance and arrhythmias. Physical exam signs
include those indicative of right heart failure: right ventricular
heave, a systolic ejection murmur in the left upper sternal border,
and a persistently split second heart sound. These patients can have
a diastolic murmur due to tricuspid stenosis and eventually can
develop hypoxemia relatively refractory to oxygen supplementa-
tion. Pulmonary hypertension develops in approximately 15% of
patients with an ASD.15
Atrial septal defects are considered appropriate for closure if the
patient has symptoms related to the shunt, including exercise
intolerance, fatigue, dyspnea, heart failure, paroxysmal embolismor
platypnoea-orthodeoxia syndrome.15 A high pulmonary-to-
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closure, although the level at which to consider closure is debated:
the AHA recommends closure for ﬂow ratios >1.5:1 in children,
recommendations are not as well established in adults.4 Closure is
generally avoided in severe pulmonary hypertension or those with
pulmonary vascular resistances greater than 15 Woods units (1200
dynes). This value comes from a large retrospective observational
study of 702 patients with ASD from 1953–1972. 40 (6%) of these
patients had pulmonary hypertension. 26 received surgical closure
and of these, and 22 patients were alive at follow-up. All patients
alive at follow-up had PVR< 15 Woods’ units. All 4 with PVR> 15
Woods’ units who had received surgical closure did not survive to
follow-up. Of the 14who receivedmedical management, 6 of 9with
PVR of 15 or greater were alive at follow-up.16
Surgical intervention should be considered in those with
secundum ASD without severe pulmonary hypertension. A
randomized controlled trial evaluated the outcomes of surgical
versus medical treatment in 473 patients with an ASD greater than
40 years-old with mPAP< 70 and Qp/Qs> 1.5:1. The medical
management group had an overall higher risk of major cardiovas-
cular events and a trend towards increased mortality when
compared to the surgical intervention group.1
An increasing number of patients are being considered for
percutaneous closure of secundum ASDs. A percutaneous catheter-
based closure can be used in these patients when there is adequate
rim tissue surrounding the defect, the defect is not too large for
percutaneous closure devices, and there is no other signiﬁcant
cardiac abnormality that precludes percutaneous closure. Compli-
cations of percutaneous closure are rare and include residual shunt,
malpositioning, arrhythmias, device erosion, and thrombus
formation with or without cerebral embolization. After closure,
a TEE is performed to ensure adequate repair. The patient should
continue on aspirin and clopidogrel for at least six months to
prevent thrombus formation.10 These patients are generally placed
on antibiotic prophylaxis to prevent endocarditis for the ﬁrst six
months post-closure.17
Although severe pulmonary hypertension is still generally
considered a contraindication to ASD closure, there are now studies
supporting safe and successful closure of ASD associated with
pulmonary hypertension using percutaneous closure devices.3
Pulmonary arterial pressures improve following ASD closure,
although less than 50% result in normalization of the PAP.2 There
are several case reports outlining successful closure of ASDs in
patients with severe pulmonary hypertension with concomitant
use of IV epoprostenol, bosentan or both.5,7,8,14
3. Outcome
In this patient, a 30 mm Amplatzer septal device was placed
percutaneously. The patient was continued on aspirin for life, and
Plavix and antibiotics for the next 6 months. He is tolerating CPAP.
Repeated echocardiograms performed after ASD closure showed
resolution of shunt physiology with appropriate placement of the
inter-atrial septal device. The patient still has right atrial and
ventricular dilation, with pulmonary artery pressures still esti-
mated as being elevated by echocardiogram. He is symptomatically
improved and off of supplemental oxygen, with most recent room
air oxygen saturation of 96%.Conﬂict of interest
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